Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
12 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to GT Biopharma, Inc.’s names, not what it holds today.
Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
7
1 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'95'99'00'01'02'12'19'20'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name4 counted
Oxis International Inc. a former name
US, as the owner printed on each patent
1 publishedGT BIOPHARMA, INC. its own name
named as the applicant on its applications, in US
3 publishedGT BioPharma, Inc. its own name
US, as the owner printed on each patent
3 publishedOxis International S.A. a former name
US, as the owner printed on each patent. 2 more under the same name are not counted (printed in FR)
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jun 18, 2002 | 6,407,083 | Uses of novel organoselenium compounds with pro-oxidant activity | Organic fine chemistry | Oxis International Inc. |
| Jul 17, 2001 | 6,262,073 | Pharmaceutical methods of use of 5-substituted and 5,5 disubstituted-3,4-dihydroxy-2(5H)-furanones | Organic fine chemistry | Oxis International Inc. |
| May 22, 2001 | 6,235,495 | Methods for the quantitation of oxidized glutathione | Analysis of biological materials | Oxis International Inc. |
| Oct 24, 2000 | 6,136,832 | 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones and methods of use therefor | Organic fine chemistry | Oxis International Inc. |
| Oct 10, 2000 | 6,130,212 | Use of novel organoselenium compounds as pro-oxidizing agents, their methods of preparation and pharmaceutical compositions and application thereof | Organic fine chemistry | Oxis International S.A. |
| Aug 15, 2000 | 6,103,746 | Methods and compositions for the protection of mitochondria | Pharmaceuticals | Oxis International Inc. |
| Mar 21, 2000 | 6,040,328 | Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use | Pharmaceuticals | Oxis International S.A. |
| Jan 4, 2000 | 6,010,685 | Skin protectant comprising 5-substituted and 5,5-disubstituted 3,4-dihydroxy-2(5H)-furanones | Organic fine chemistry | Oxis International Inc. |
| Dec 21, 1999 | 6,005,000 | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor | Organic fine chemistry | Oxis International Inc. |
| Oct 26, 1999 | 5,973,009 | Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use | Pharmaceuticals | Oxis International S.A. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 8, 2025 | 2025/0145715 | B7-H3 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF | Biotechnology | GT BIOPHARMA, INC. |
| Dec 26, 2024 | 2024/0425597 | PD-L1 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF | Biotechnology | GT BIOPHARMA, INC. |
| Oct 13, 2022 | 2022/0324972 | IMMUNOTHERAPY COMPOUNDS AND METHODS | Biotechnology | GT BIOPHARMA, INC. |
| Feb 20, 2020 | 2020/0054611 | USE AND COMPOSITION FOR TREATING MYASTHENIA GRAVIS AND OTHER MYASTHENIC SYNDROMES | Pharmaceuticals | GT BioPharma, Inc. |
| Jan 2, 2020 | 2020/0000756 | NEOSTIGMINE COMBINATION AND COMPOSITIONS | Pharmaceuticals | GT BioPharma, Inc. |
| Dec 5, 2019 | 2019/0365694 | COMPOSITION OF MATTER AND USE THEREOF FOR PREVENTING AND TREATING MOTION SICKNESS | Pharmaceuticals | GT BioPharma, Inc. |
| Jun 7, 2012 | 2012/0141611 | METHODS AND COMPOSITIONS USING ERGOTHIONEINE TO TREAT A VARIETY OF HEALTH RELATED FACTORS | Pharmaceuticals | Oxis International Inc. |
What it applied for, 2024 to 2025: Biotechnology 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.